Tuberculin skin test before biologic and targeted therapies: does the same rule apply for all?
Abstract This study aimed to compare Tuberculin Skin Test (TST) and QuantiFERON®-TB Gold In-Tube (QFT–GIT) test in rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients scheduled for biological and targeted synthetic disease modifying anti-rheumatic drugs (DMARDs) in a Bacillus Calmette-Guérin-vaccinated population. Adult RA (n = 206) and SpA (n = 392) patients from the TReasure database who had both TST and QFT–GIT prior to initiation of biological and targeted synthetic DMARDs were included in the study. Demographic and disease characteristics along with pre-biologic DMARD and steroid use were recorded. The distribution of TST and performance with respect to QFT–GIT were compared between RA and SpA groups. Pre-biologic conventional DMARD and steroid use was higher in the RA group. TST positivity rates were 44.2% in RA and 69.1% in SpA for a 5 mm cutoff (p < 0.001). Only 8.9% and 15% of the patients with RA and SpA, respectively, tested positive by QFT–GIT. The two tests poorly agreed in both groups at a TST cutoff of 5 mm and increasing the TST cutoff only slightly increased the agreement. Among age, sex, education and smoking status, pre-biologic steroid and conventional DMARD use, disease group, and QFT–GIT positivity, which were associated with a 5 mm or higher TST, only disease group (SpA) and QFT–GIT positivity remained significant in multiple logistic regression. TST positivity was more pronounced in SpA compared to that in RA and this was not explainable by pre-biologic DMARD and steroid use. The agreement of TST with QFT–GIT was poor in both groups. Using a 5 mm TST cutoff for both diseases could result in overestimating LTBI in SpA..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Rheumatology international - 42(2022), 10 vom: 29. Apr., Seite 1797-1806 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
İlgen, Ufuk [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Arthritis |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022 |
|---|
| doi: |
10.1007/s00296-022-05134-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR048004936 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR048004936 | ||
| 003 | DE-627 | ||
| 005 | 20230519092948.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220903s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00296-022-05134-z |2 doi | |
| 035 | |a (DE-627)SPR048004936 | ||
| 035 | |a (SPR)s00296-022-05134-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a İlgen, Ufuk |e verfasserin |0 (orcid)0000-0001-6443-6426 |4 aut | |
| 245 | 1 | 0 | |a Tuberculin skin test before biologic and targeted therapies: does the same rule apply for all? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022 | ||
| 520 | |a Abstract This study aimed to compare Tuberculin Skin Test (TST) and QuantiFERON®-TB Gold In-Tube (QFT–GIT) test in rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients scheduled for biological and targeted synthetic disease modifying anti-rheumatic drugs (DMARDs) in a Bacillus Calmette-Guérin-vaccinated population. Adult RA (n = 206) and SpA (n = 392) patients from the TReasure database who had both TST and QFT–GIT prior to initiation of biological and targeted synthetic DMARDs were included in the study. Demographic and disease characteristics along with pre-biologic DMARD and steroid use were recorded. The distribution of TST and performance with respect to QFT–GIT were compared between RA and SpA groups. Pre-biologic conventional DMARD and steroid use was higher in the RA group. TST positivity rates were 44.2% in RA and 69.1% in SpA for a 5 mm cutoff (p < 0.001). Only 8.9% and 15% of the patients with RA and SpA, respectively, tested positive by QFT–GIT. The two tests poorly agreed in both groups at a TST cutoff of 5 mm and increasing the TST cutoff only slightly increased the agreement. Among age, sex, education and smoking status, pre-biologic steroid and conventional DMARD use, disease group, and QFT–GIT positivity, which were associated with a 5 mm or higher TST, only disease group (SpA) and QFT–GIT positivity remained significant in multiple logistic regression. TST positivity was more pronounced in SpA compared to that in RA and this was not explainable by pre-biologic DMARD and steroid use. The agreement of TST with QFT–GIT was poor in both groups. Using a 5 mm TST cutoff for both diseases could result in overestimating LTBI in SpA. | ||
| 650 | 4 | |a Arthritis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Spondyloarthritis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Interferon-gamma release tests |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Tuberculin test |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Latent tuberculosis |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Karadağ, Ömer |0 (orcid)0000-0002-3443-3117 |4 aut | |
| 700 | 1 | |a Emmungil, Hakan |0 (orcid)0000-0001-5184-4404 |4 aut | |
| 700 | 1 | |a Küçükşahin, Orhan |0 (orcid)0000-0003-4530-2304 |4 aut | |
| 700 | 1 | |a Koca, Süleyman Serdar |0 (orcid)0000-0003-4995-430X |4 aut | |
| 700 | 1 | |a Erden, Abdülsamet |0 (orcid)0000-0002-8084-2018 |4 aut | |
| 700 | 1 | |a Bes, Cemal |0 (orcid)0000-0002-1730-2991 |4 aut | |
| 700 | 1 | |a Alpay Kanıtez, Nilüfer |0 (orcid)0000-0003-1185-5816 |4 aut | |
| 700 | 1 | |a Dalkılıç, Ediz |0 (orcid)0000-0001-8645-2670 |4 aut | |
| 700 | 1 | |a Akar, Servet |0 (orcid)0000-0002-3734-1242 |4 aut | |
| 700 | 1 | |a Mercan, Rıdvan |0 (orcid)0000-0003-1537-2192 |4 aut | |
| 700 | 1 | |a Çınar, Muhammet |0 (orcid)0000-0002-6150-3539 |4 aut | |
| 700 | 1 | |a Kaşifoğlu, Timuçin |0 (orcid)0000-0002-9941-5884 |4 aut | |
| 700 | 1 | |a Gönüllü, Emel |0 (orcid)0000-0002-6990-4206 |4 aut | |
| 700 | 1 | |a Kimyon, Gezmiş |0 (orcid)0000-0003-3775-639X |4 aut | |
| 700 | 1 | |a Ersözlü, Duygu |0 (orcid)0000-0001-6172-7762 |4 aut | |
| 700 | 1 | |a Atagündüz, Pamir |0 (orcid)0000-0002-6393-7461 |4 aut | |
| 700 | 1 | |a Kılıç, Levent |0 (orcid)0000-0002-3102-5847 |4 aut | |
| 700 | 1 | |a Ertenli, İhsan |0 (orcid)0000-0002-3904-0769 |4 aut | |
| 700 | 1 | |a Yazısız, Veli |0 (orcid)0000-0002-3176-4850 |4 aut | |
| 700 | 1 | |a Ateş, Aşkın |0 (orcid)0000-0003-1966-3333 |4 aut | |
| 700 | 1 | |a Kiraz, Sedat |0 (orcid)0000-0003-2802-6061 |4 aut | |
| 700 | 1 | |a Kalyoncu, Umut |0 (orcid)0000-0001-7129-2109 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology international |d Berlin : Springer, 1981 |g 42(2022), 10 vom: 29. Apr., Seite 1797-1806 |w (DE-627)SPR00382473X |w (DE-600)1464208-6 |x 1437-160X |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2022 |g number:10 |g day:29 |g month:04 |g pages:1797-1806 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00296-022-05134-z |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2022 |e 10 |b 29 |c 04 |h 1797-1806 | ||